NASDAQ$SHC
Sotera Health Company · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Sotera Health's first quarter of 2021 resulted in double-digit revenue growth, meaningful net income growth, and double-digit Adjusted EBITDA growth.
Sotera Health reported a strong start to 2021 with double-digit revenue and Adjusted EBITDA growth. Net revenues for Q1 2021 increased by 13% to $212 million, and net income was $11 million, or $0.04 per diluted share. The company reaffirmed its 2021 outlook.
- Q1 2021 net revenues increased 13% to $212 million compared to Q1 2020.
- Q1 2021 net income was $11 million, or $0.04 per diluted share, compared to a net loss of $2 million in Q1 2020.
- Q1 2021 Adjusted EPS increased 80% to $0.18, compared to $0.10 in Q1 2020.
- The company reaffirmed its 2021 outlook.
Headline financials
Revenue & EPS history
Sotera Health · Revenue · Quarterly
$212M
Revenue by segment
Sotera Health · $212M total across 3 segments · Q1 2021
- Sterigenics$131M+11.8%61.8%
- Nelson Labs$55.1M+16.5%26.0%
- Nordion$25.9M+9.7%12.2%
Forward guidance
Sotera Health reaffirmed its 2021 outlook, which was first provided on March 9, 2021.
Tailwinds
- Net revenues in the range of $890 million to $920 million, representing growth of approximately 9% to 12%, compared to the prior year.
- Adjusted EBITDA in the range of $465 million to $485 million, representing growth of approximately 11% to 16%, compared to the prior year.
- Tax rate applicable to Adjusted Net Income of approximately 28%.
- Adjusted EPS in the range of $0.78 to $0.86.
- Net leverage reduction of approximately 3⁄4 of a turn.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
-2.7%
Avg return
Earnings day
-3.0%
Avg return
5 days after
-2.4%
Avg return
30 days after
25%
6 / 24 earnings
Positive
+11.2%
Q2 2024
Best reaction
-15.9%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.3% | +2.6% | +1.2% | |
| Q4 2025 | -0.5% | -7.1% | -22.6% | |
| Q3 2025 | -1.1% | -5.6% | -0.3% | |
| Q1 2025 | +5.2% | +11.7% | +6.4% | |
| Q4 2024 | -10.0% | -15.9% | -13.7% | |
| Q3 2024 | +2.0% | +1.8% | -17.9% | |
| Q2 2024 | +11.2% | +10.1% | +16.6% | |
| Q1 2024 | -2.2% | +1.8% | -0.8% | |
| Q4 2023 | -12.3% | -14.7% | -29.6% | |
| Q3 2023 | +1.2% | +5.8% | +10.6% | |
| Q2 2023 | -3.7% | -7.1% | -13.4% | |
| Q1 2023 | -7.5% | -7.9% | -9.2% | |
| Q4 2022 | -0.5% | +3.9% | +2.0% | |
| Q3 2022 | -10.6% | -7.7% | +28.6% | |
| Q2 2022 | +2.1% | +4.2% | -6.7% | |
| Q1 2022 | -2.8% | -5.4% | +3.7% | |
| Q4 2021 | -8.4% | -11.4% | -1.0% | |
| Q4 2019 | -8.4% | -11.4% | -1.0% | |
| Q3 2021 | -15.9% | -13.7% | -20.0% | |
| Q2 2021 | -0.7% | -6.3% | +1.0% | |
| Q2 2020 | -0.7% | -6.3% | +1.0% | |
| Q1 2021 | -5.4% | -3.4% | +3.5% | |
| Q1 2020 | -5.4% | -3.4% | +3.5% | |
| Q4 2020 | +8.9% | +13.6% | +1.4% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro